Regeneron Seeks EU Fast-Track Review For Hearing Loss Gene Therapy Following Swift US Approval

 
• By Neena Brizmohun
  
Calendar Pages Flipping
The EU accelerated assessment mechanism can cut the time it takes to review drug marketing applications by months (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from EU CHMP

More from Product Reviews